Literature DB >> 26837891

Modulation of microRNAs expression in hematopoietic stem cells treated with sodium butyrate in inducing fetal hemoglobin expression.

Behnoosh Tayebi1, Fatemeh Abrishami1, Shaban Alizadeh2, Neda Minayi2, Mozhdeh Mohammadian3,4, Masoud Soleimani5, Ali Dehghanifard6, Hossein Atwan7, Monireh Ajami1, Mansoureh Ajami5.   

Abstract

Context Inherited hemoglobin diseases are the most common single-gene disorders. Induction of fetal hemoglobin in beta hemoglobin disorders compensate for abnormal chain and ameliorate the clinical complications. Sodium butyrate is used conventionally for fetal hemoglobin induction; it can be replaced by safer therapeutic tools like microRNAs, small non-coding RNAs that control number of epigenetic mechanisms. Objective In this study, we compared the changes in the microRNAs of differentiated erythroid cells between control and sodium butyrate treated groups. The objective is to find significant association between these changes and gamma chain up regulation. Materials and methods First, CD133+  hematopoietic stem cells were isolated from cord blood by magnetic cell sorting (MACS) technique. After proliferation, the cells were differentiated to erythroid lineage in culture medium by EPO, SCF, and IL3. Meanwhile, the test group was treated with sodium butyrate. Then, gamma chain upregulation was verified by qPCR technique. Finally, microRNA profiling was performed through microarray assay and some of them confirmed by qPCR. Result Results demonstrated that gamma chain was 5.9-fold upregulated in the treated group. Significant changes were observed at 76 microRNAs, in which 20 were up-regulated and 56 were down-regulated. Discussion Five of these microRNAs including U101, hsa-miR-4726-5p, hsa-miR7109 5p, hsa-miR3663, and hsa-miR940 had significant changes in expression and volume. Conclusion In conclusion, it can be assumed that sodium butyrate can up-regulate gamma chain gene, and change miRNAs expression. These results can be profitable in future studies to find therapeutic goal suitable for such disorders.

Entities:  

Keywords:  Fetal hemoglobin; hematopoietic stem cell; microRNA; microarray; sickle cell anemia; sodium butyrate; thalassemia

Mesh:

Substances:

Year:  2016        PMID: 26837891     DOI: 10.3109/21691401.2016.1138487

Source DB:  PubMed          Journal:  Artif Cells Nanomed Biotechnol        ISSN: 2169-1401            Impact factor:   5.678


  6 in total

Review 1.  Erythrocyte microRNAs: a tiny magic bullet with great potential for sickle cell disease therapy.

Authors:  Henu Kumar Verma; Yashwant Kumar Ratre; L V K S Bhaskar; Raffaella Colombatti
Journal:  Ann Hematol       Date:  2021-01-04       Impact factor: 3.673

Review 2.  Pathophysiology and recent therapeutic insights of sickle cell disease.

Authors:  Firdosh Shah; Mitesh Dwivedi
Journal:  Ann Hematol       Date:  2020-03-10       Impact factor: 3.673

3.  MIR29B mediates epigenetic mechanisms of HBG gene activation.

Authors:  Athena Starlard-Davenport; Alana Smith; Luan Vu; Biaoru Li; Betty S Pace
Journal:  Br J Haematol       Date:  2019-03-19       Impact factor: 6.998

Review 4.  Single Nucleotide Polymorphisms in XMN1-HBG2, HBS1L-MYB, and BCL11A and Their Relation to High Fetal Hemoglobin Levels That Alleviate Anemia.

Authors:  Siti Nur Nabeela A'ifah Mohammad; Salfarina Iberahim; Wan Suriana Wan Ab Rahman; Mohd Nazri Hassan; Hisham Atan Edinur; Maryam Azlan; Zefarina Zulkafli
Journal:  Diagnostics (Basel)       Date:  2022-06-02

5.  Integrated analysis of competitive endogenous ribose nucleic acids (ceRNAs)-related regulatory networks in invasive and non-invasive non-functioning pituitary adenomas (NFPAs).

Authors:  Jiangtao Liu; Kaixuan Wang; Hongming Ji; Gangli Zhang; Shengli Chen; Shiyuan Zhang; Fake Lu; Changchen Hu
Journal:  Front Surg       Date:  2022-09-29

6.  Solamargine inhibits the growth of hepatocellular carcinoma and enhances the anticancer effect of sorafenib by regulating HOTTIP-TUG1/miR-4726-5p/MUC1 pathway.

Authors:  Qing Tang; Xiaojuan Li; Yun Chen; Shunqin Long; Yaya Yu; Honghao Sheng; Sumei Wang; Ling Han; Wanyin Wu
Journal:  Mol Carcinog       Date:  2022-01-17       Impact factor: 5.139

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.